Do you want BuboFlash to help you learning these things? Or do you want to add or correct something? Click here to log in or create user.



Question
Sevoflurane is administered clinically in an amount that is 1.3- to 1.4-fold the MAC (mini- mum alveolar concentration), or the dose at which 50% of the patients do not move on surgical stimulation. The MAC can be lethal if the volume percentage delivered is increased to [...]fold and maintained for a prolonged period of time.
Answer
1.7- to 2.0-

Question
Sevoflurane is administered clinically in an amount that is 1.3- to 1.4-fold the MAC (mini- mum alveolar concentration), or the dose at which 50% of the patients do not move on surgical stimulation. The MAC can be lethal if the volume percentage delivered is increased to [...]fold and maintained for a prolonged period of time.
Answer
?

Question
Sevoflurane is administered clinically in an amount that is 1.3- to 1.4-fold the MAC (mini- mum alveolar concentration), or the dose at which 50% of the patients do not move on surgical stimulation. The MAC can be lethal if the volume percentage delivered is increased to [...]fold and maintained for a prolonged period of time.
Answer
1.7- to 2.0-
If you want to change selection, open original toplevel document below and click on "Move attachment"

Parent (intermediate) annotation

Open it
nically in an amount that is 1.3- to 1.4-fold the MAC (mini- mum alveolar concentration), or the dose at which 50% of the patients do not move on surgical stimulation. The MAC can be lethal if the volume percentage delivered is increased to <span>1.7- to 2.0-fold and maintained for a prolonged period of time.<span><body><html>

Original toplevel document (pdf)

cannot see any pdfs

Summary

statusnot learnedmeasured difficulty37% [default]last interval [days]               
repetition number in this series0memorised on               scheduled repetition               
scheduled repetition interval               last repetition or drill

Details

No repetitions


Discussion

Do you want to join discussion? Click here to log in or create user.